TrialCancer research2016

Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.

Keith L Knutson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.